To perform and complete the study close out of the protocol, which is to compare the safety, tolerance, virologic and pharmacologic responses of representatives of these two antiretroviral (ARV) classes in HIV-infected pregnant women presenting late for care. HIV-infected pregnant women presenting for care late in pregnancy need a rapid response and effective ARV therapy to minimize the risk of HIV transmission to their newborn. No data are available comparing the effects of non-nucleotide reverse transcriptase inhibitors (NNRTIs) and Integrase Inhibitors (IIs) in pregnant women. Completion of the close out activities of this protocol will provide the final dataset/information. The study close-out activities include the completion of the manuscript, complete data analysis and store data and samples to the NICHD DASH repository.